Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Haemonetics (HAE) over the last 17 years, with Q4 2025 value amounting to -$11.1 million.

  • Haemonetics' Change in Receivables fell 72439.3% to -$11.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$17.7 million, marking a year-over-year decrease of 1024561.4%. This contributed to the annual value of -$7.0 million for FY2025, which is 12875.21% down from last year.
  • Haemonetics' Change in Receivables amounted to -$11.1 million in Q4 2025, which was down 72439.3% from $7.3 million recorded in Q3 2025.
  • In the past 5 years, Haemonetics' Change in Receivables registered a high of $30.6 million during Q4 2023, and its lowest value of -$25.5 million during Q2 2021.
  • Its 5-year average for Change in Receivables is $2.2 million, with a median of $911000.0 in 2023.
  • The largest annual percentage gain for Haemonetics' Change in Receivables in the last 5 years was 61857.07% (2024), contrasted with its biggest fall of 706078.43% (2024).
  • Haemonetics' Change in Receivables (Quarter) stood at $9.2 million in 2021, then fell by 20.63% to $7.3 million in 2022, then skyrocketed by 317.63% to $30.6 million in 2023, then plummeted by 94.21% to $1.8 million in 2024, then crashed by 724.39% to -$11.1 million in 2025.
  • Its Change in Receivables stands at -$11.1 million for Q4 2025, versus $7.3 million for Q3 2025 and -$3.6 million for Q2 2025.